The SST-14 Restoration Protocol

The Central Argument

Intramuscular immunoglobulin therapy (IMIG) is proposed as a treatment for immune-derived autism (IDA) through a specific mechanism: it removes the autoantibody and chronic immune activation load that is suppressing SST-14 interneuron transcription through NF-κB and the cytokine-driven CBP competition at the somatostatin gene CRE. What IMIG cannot do is simultaneously address the adenosine-driven adenylyl cyclase suppression that is starving CREB of cAMP from a second independent direction.

This document presents the mechanistic argument that a carefully sequenced supplement cascade can address the same final common pathway — SST-14 transcriptional restoration — through convergent but distinct molecular angles. No single compound addresses both suppression mechanisms simultaneously. But a sequenced combination can address both through five different molecular angles, while simultaneously building the metabolic infrastructure that SST-14 interneuron recovery requires.

Biological Context

2.1 The Founding Conditions

The biological cascade leading to SST-14 silencing originates in gut pH dysregulation. Multiple common environmental conditions produce this dysregulation simultaneously: C-section delivery bypassing vaginal microbiome seeding; formula feeding replacing breast milk oligosaccharides; antibiotic exposure disrupting commensal bacteria; maternal oral contraceptive use depleting zinc and compromising parietal cell carbonic anhydrase function; early H. pylori infection alkalinizing the gastric environment directly.

Elevated gut pH above 4.0 disables pepsin-mediated proline bond cleavage. Intact casomorphin and gliadorphin fragments — opioid peptides from incompletely digested casein and gluten — accumulate, penetrate the gut barrier, block the CD26 receptor where adenosine deaminase docks, and activate CCK-driven SST-28 overexpression in intestinal D-cells simultaneously. Adenosine accumulates. The methionine synthase cycle slows. LPS crosses the compromised gut barrier into systemic circulation. The innate immune alarm activates. NF-κB moves in. The two transcriptional suppression mechanisms are now both active.

2.2 Constitutional Susceptibility — Why Only Some Individuals Cross the Threshold

The founding conditions described above are common across the general pediatric population. Most children exposed to them do not develop IDA. The reason is constitutional biology: the genetically and immunologically determined capacity at each cascade step determines how much environmental load the system can absorb before that step fails. Seven tipping points have been identified — gastric acid production capacity, CD26/DPP-IV adenosine clearance capacity, methylation cycle reserve, inflammatory resolution capacity, kynurenine pathway excitotoxic branch bias, mitochondrial excitotoxic buffering reserve, and HLA-mediated autoantibody susceptibility.

2.3 The Self-Reinforcing Biological Latch — Why the Protocol Requires Months

A critical feature of IDA that determines the expected timeline is the self-reinforcing latch. SST-14 interneurons normally provide anti-inflammatory inhibitory tone to microglia and suppress the A1 reactive astrocyte state. When SST-14 production falls, microglial activation increases, cytokine production rises, NF-κB activates more strongly, CREB is suppressed further, SST-14 production falls further. The system cannot self-correct because the correction mechanism has been disabled.

The implication for the protocol timeline is direct: unwinding a self-reinforcing latch requires sustained multi-angle intervention over months, not weeks. Each compound in the cascade reduces a different component of the suppression simultaneously. The biological latch unwinds gradually — and the first observable functional signals of SST-14 restoration typically emerge 8–16 weeks into a well-implemented protocol.

2.4 Patient Selection — Who This Protocol Is Designed For

The protocol is most appropriate for patients in the IDA biomarker-defined subgroup. The following biomarker panel identifies the highest-probability responders:

The SST-14 Transcriptional Suppression Problem

The SST-14 Restoration white paper identifies two independent mechanisms that simultaneously silence SST-14 gene transcription in IDA:

Mechanism 1 — NF-κB-mediated CREB suppression. Chronic pro-inflammatory cytokines activate NF-κB, which competes with CREB for the co-activator CBP (CREB-binding protein). CBP is present in limited quantities and cannot be rapidly upregulated. NF-κB wins this competition under chronic inflammatory conditions, redirecting CBP to the inflammatory transcriptional program. Without CBP, CREB cannot open the CRE lock on the somatostatin gene promoter. Simultaneously, NF-κB recruits HDAC enzymes to compact the chromatin around the CRE, making the lock physically harder to reach.

Mechanism 2 — Adenosine-driven adenylyl cyclase suppression. Casomorphin and gliadorphin block the CD26 receptor where adenosine deaminase docks, preventing adenosine clearance. Accumulated adenosine activates inhibitory Gαi-coupled receptors on SST-14 interneurons, suppressing adenylyl cyclase. Less adenylyl cyclase activity means less cAMP. Less cAMP means PKA cannot phosphorylate CREB. Unphosphorylated CREB cannot bind the CRE or recruit CBP even if CBP were available.

How IMIG Addresses the Suppression

IMIG works upstream of both suppression mechanisms through immune modulation. Passive transfer of regulatory antibodies dampens NK cell and T-cell overactivation, reducing the pro-inflammatory cytokine production that drives NF-κB activation (Mechanism 1 relief from upstream). FcγRIIB upregulation reduces IL-6, TNF-α, and IFN-γ — the cytokines that activate IDO1, maintaining tryptophan depletion and NAD⁺ insufficiency. Reduction in autoantibody-mediated receptor disruption at neuronal surfaces may partially restore G-protein coupling efficiency, improving adenylyl cyclase responsiveness (indirect Mechanism 2 relief).

IMIG's power is that it addresses the root cause of Mechanism 1 directly — the chronic immune activation that sustains NF-κB. It works from the top down. The supplement cascade works from the bottom up and laterally, targeting downstream nodes of both mechanisms simultaneously. Together they provide convergent multi-angle attack on the same final target.

The Supplement Cascade — Five Molecular Angles

The supplement cascade targets the same two suppression mechanisms through five distinct molecular angles of attack. The key insight is that these compounds do not merely reduce inflammation generally — each addresses a specific node in either the NF-κB-CBP-CREB pathway or the CD26-adenosine-adenylyl cyclase-cAMP pathway.

Angle One — Reducing NF-κB Activation (Mechanism 1 Relief)

Sulforaphane activates Nrf2, upregulating antioxidant enzyme production and simultaneously inhibiting NF-κB activity through Nrf2-dependent suppression of NF-κB nuclear translocation. Singh et al. (PNAS 2014) demonstrated significant improvements in SRS and ABC scores in a randomized controlled trial of sulforaphane in ASD. Sulforaphane does not replace immunoglobulin therapy's autoantibody and cytokine modulation — but it reduces the ongoing cytokine-driven NF-κB activation that both IMIG and sulforaphane are working to suppress from different angles.

Luteolin inhibits mast cell degranulation, reduces microglial activation, and downregulates NF-κB signaling through multiple pathways including IκB kinase inhibition. It also inhibits CD38 — the primary NADase competing with SIRT1 for the NAD⁺ pool — providing a second mechanism of action relevant to Mechanism 2. Theoharides et al. documented significant improvements in ASD behavioral measures in a clinical study of luteolin-containing formulation.

Angle Two — Restoring the NAD⁺/cAMP Axis (Mechanism 2 Relief)

NMN and NR (nicotinamide mononucleotide and nicotinamide riboside) are NAD⁺ precursors that bypass the rate-limiting synthetic steps to directly replenish cellular NAD⁺. This addresses the Mechanism 2 arm at the mitochondrial energy level: IDO1-driven tryptophan diversion depletes NAD⁺, preventing the SST-14 interneuron from maintaining the tonic high-frequency firing required for coordinated neuropeptide cascade output. NMN/NR does not directly restore adenylyl cyclase activity, but it restores the ATP substrate that adenylyl cyclase requires, and the NAD⁺/SIRT1 axis that modulates the inflammatory response.

Forskolin is a direct adenylyl cyclase activator — the only supplement in the cascade that directly addresses the adenylyl cyclase suppression at the enzymatic level. Seamon and Daly (1986) established its mechanism as direct activation of the catalytic subunit of adenylyl cyclase, increasing intracellular cAMP independently of G-protein coupling. This is the most direct downstream address of Mechanism 2 in the cascade: when adenosine has suppressed adenylyl cyclase through Gαi, forskolin bypasses the Gαi suppression to activate the enzyme directly. Forskolin is the terminal compound in the cascade precisely because its direct adenylyl cyclase activation is most effective when NF-κB has already been reduced by sulforaphane and luteolin, and when NAD⁺ has been restored by NMN/NR.

Angle Three — Senolytic SASP Clearance

Fisetin is a senotherapeutic flavonoid that selectively clears senescent cells through apoptosis induction. Senescent cells produce the senescence-associated secretory phenotype (SASP) — a chronic low-grade inflammatory secretome that contributes to NF-κB activation independently of the acute immune response that IMIG and sulforaphane target. Yousefzadeh et al. (EBioMedicine 2018) demonstrated that fisetin extends healthspan and reduces inflammatory markers in aging models. In the IDA context, SASP clearance removes a chronic upstream inflammatory input that neither immunotherapy nor acute NF-κB suppression addresses.

Sequencing Logic — Why Order Matters

The supplement cascade is not a stack of simultaneous additions. It is a staged biological preparation in which each compound creates better conditions for the next. The sequence is mechanistically determined — not arbitrary.

IMIG and the Supplement Cascade — A Synergistic Combination

The supplement cascade and IMIG are not competing therapeutic strategies. They are convergent interventions that attack the same two suppression mechanisms from opposite directions simultaneously. When both are running, every node of the suppression is being addressed from at least two independent directions at once.

The Infrastructure Preparation Argument

The most important synergy argument is about what the supplement cascade does to prepare the biological environment before IMIG is initiated. IMIG removes the transcriptional suppression. But that removal is only as effective as the metabolic infrastructure beneath it. SST-14 interneurons that have been running in a NAD⁺-depleted, glutathione-insufficient, SASP-inflamed environment for years cannot immediately resume tonic high-frequency firing the moment NF-κB begins to recede — even if the transcriptional suppression is lifted.

Running the supplement cascade for two to four months before IMIG initiation builds that infrastructure. It ensures that when IMIG begins removing the transcriptional ceiling, the metabolic floor is already in place to respond. The expected clinical result is a faster and more complete IMIG response than would be achieved without the preparatory cascade.

Expected Clinical Signals of SST-14 Restoration

If the supplement cascade is producing meaningful SST-14 transcriptional restoration, the following functional signals would be expected over a 3–12 month trajectory. These are the same signals expected from IMIG in State 1 and State 2 patients — the signal profile reflects the shared molecular target, not the specific intervention producing it.

The absence of these signals after a well-implemented 6-month protocol should prompt biomarker reassessment — checking whether the K:T ratio and cytokine panel have moved, whether homocysteine has normalized, and whether the Cunningham Panel autoantibodies have changed. If biomarkers have not moved, the upstream driving conditions remain active and the protocol is operating against an unaddressed source.

Conclusion

The SST-14 transcriptional suppression problem has two independent mechanisms. IMIG addresses both through upstream immune modulation — clearing the autoantibody and cytokine load that drives both NF-κB activation and IDO1-driven adenosine accumulation. The supplement cascade addresses both mechanisms through convergent bottom-up and lateral interventions: sulforaphane and luteolin attacking NF-κB from two molecular angles; NMN/NR and luteolin-CD38 inhibition restoring the NAD⁺ axis; fisetin clearing the SASP chronic inflammatory background; and forskolin directly activating adenylyl cyclase to bypass the Gαi suppression that no other compound in the cascade directly addresses.

The two pathways converge on the same molecular target: phosphorylated CREB occupying the CRE binding site on the somatostatin gene promoter, driving SST-14 transcription, restoring tonic interneuron output, and allowing the downstream neuropeptide cascade — oxytocin, VIP, secretin — to recover its upstream coordination.